India Idiopathic Pulmonary Fibrosis Treatment Market

Market Overview:

The India idiopathic pulmonary fibrosis treatment market size reached US$ 26.8 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 44.9 Million by 2028, exhibiting a growth rate (CAGR) of 8.75% during 2023-2028.

Idiopathic pulmonary fibrosis (IPF) refers to an infectious lung disease that causes the buildup of scar tissues in the lungs, which reduces their oxygen-carrying functionalities. It is diagnosed through various chest imaging evaluations, including lung biopsies, antibody tests, and pulmonary function tests. IPF is treated by prescribing anti-fibrotic drugs containing nintedanib and pirfenidone salts, which slows the rate of scar tissue formation and controls the associated symptoms. Supportive therapeutic options, including palliative care and oxygen therapy, are also provided as effective treatment methods for IPF.

India Idiopathic Pulmonary Fibrosis Treatment Market Trends:

The increasing prevalence of fibrotic diseases, especially in the geriatric population, is primarily fueling the India IPF treatment market growth. The rising awareness regarding the availability of effective strategies for preventing and managing IPF is acting as another growth-inducing factor. In line with this, rapid economic growth and advancements in diagnostic and treatment methods are further propelling the market growth. Moreover, extensive research and development (R&D) activities for introducing novel medications and increasing improvements in the healthcare infrastructure are positively influencing the market growth across the country.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the India idiopathic pulmonary fibrosis treatment market report, along with forecasts at the country and regional levels from 2023-2028. Our report has categorized the market based on drug class and end user.

Breakup by Drug Class:

• MAPK Inhibitors
• Tyrosine Inhibitors
• Autotaxin Inhibitors
   

Breakup by End User:

• Hospitals
• Long-term Care Facilities
• Others
   

Breakup by Region:

• North India
• West and Central India
• South India
• East India
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Report Coverage:

Key Questions Answered in This Report:

• How has the India idiopathic pulmonary fibrosis treatment market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the India idiopathic pulmonary fibrosis treatment market?
• What are the key regional markets?
• What is the breakup of the market based on the drug class?
• What is the breakup of the market based on the end user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the India idiopathic pulmonary fibrosis treatment market and who are the key players?
• What is the degree of competition in the industry?